<DOC>
	<DOCNO>NCT00007345</DOCNO>
	<brief_summary>Background : NSC630176 depsipeptide fermentation product Chromobacterium violaceum potent cytotoxic activity human tumor cell line vivo efficacy human tumor xenograft murine tumor ( 1-3 ) . NSC 630176 , herein refer depsipeptide , show lack cross resistance several commonly use cytotoxic agent vincristine , 5-fluorouracil , mitomycin C cyclophosphamide ( 2 ) . However , define P-glycoprotein ( Pgp ) substrate COMPARE analysis National Cancer Institute ( NCI ) drug screen cytotoxicity profile ( 4 ) . Depsipeptide member novel class antineoplastic agent , histone deacetylase inhibitor . In phase I trial conduct National Cancer Institute ( NCI ) , responses observed maximum tolerate dose ( MTD ) patient cutaneous peripheral T-cell lymphoma . Objectives : In patient cutaneous T-cell lymphoma , primary end point examine overall response rate , complete response rate duration response . In patient relapsed peripheral T-cell lymphoma , endpoint examine overall response rate complete response rate . To evaluate tolerability depsipeptide extend cycle therapy . Eligibility : Patients cutaneous T-cell lymphoma ( mycosis fungoides Sezary syndrome ) peripheral T-cell lymphoma eligible . Design : Depsipeptide administer 14 mg/m^2 , 4 hour day 1 , 8 15 . This trial accrue six cohort ; Arm 1 , patient cutaneous T-cell lymphoma less equal two prior cytotoxic chemotherapy regimens ; Arm 2 , patient peripheral T-cell lymphoma less equal two prior cytotoxic chemotherapy regimens ; Arm 3 , patient cutaneous peripheral T-cell lymphoma two prior cytotoxic chemotherapy regimens ; Arm 4 , patient mature T-cell lymphoma ; Arm 5 , replicate arm arm 1 ; Arm 6 , patient peripheral T-cell lymphoma two prior cytotoxic chemotherapy regimens ; Arm 7 , patient cutaneous T cell lymphoma receive vorinostat . Dose may adjust base toxicity .</brief_summary>
	<brief_title>Depsipeptide Treat Patients With Cutaneous T-Cell Lymphoma Peripheral T-Cell Lymphoma</brief_title>
	<detailed_description>Background : NSC630176 depsipeptide fermentation product Chromobacterium violaceum potent cytotoxic activity human tumor cell line vivo efficacy human tumor xenograft murine tumor ( 1-3 ) . NSC 630176 , herein refer depsipeptide , show lack cross resistance several commonly use cytotoxic agent vincristine , 5-fluorouracil , mitomycin C cyclophosphamide ( 2 ) . However , define P-glycoprotein ( Pgp ) substrate COMPARE analysis National Cancer Institute ( NCI ) drug screen cytotoxicity profile ( 4 ) . Depsipeptide member novel class antineoplastic agent , histone deacetylase inhibitor . In phase I trial conduct NCI , responses observed maximum tolerate dose ( MTD ) patient cutaneous peripheral T-cell lymphoma . Objectives : In patient cutaneous T-cell lymphoma , primary end point examine overall response rate , complete response rate duration response . In patient relapsed peripheral T-cell lymphoma , endpoint examine overall response rate complete response rate . To evaluate tolerability depsipeptide extend cycle therapy . Eligibility : Patients cutaneous T-cell lymphoma ( mycosis fungoides Sezary syndrome ) peripheral T-cell lymphoma eligible . Design : Depsipeptide administer 14 mg/m^2 , 4 hour day 1 , 8 15 . This trial accrue six cohort ; Arm 1 , patient cutaneous T-cell lymphoma less equal two prior cytotoxic chemotherapy regimens ; Arm 2 , patient peripheral T-cell lymphoma less equal two prior cytotoxic chemotherapy regimens ; Arm 3 , patient cutaneous peripheral T-cell lymphoma two prior cytotoxic chemotherapy regimens ; Arm 4 , patient mature T-cell lymphoma ; Arm 5 , replicate arm arm 1 ; Arm 6 , patient peripheral T-cell lymphoma two prior cytotoxic chemotherapy regimens ; Arm 7 , patient cutaneous T cell lymphoma receive vorinostat . Dose may adjust base toxicity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>INCLUSION CRITERIA : Based Inclusion Criteria outline , patient accrue one cohorts trial . Cohort chemotherapy regimens allow . Cohort Status Cohort 1 Cutaneous Tcell Lymphoma ( mycosis fungoides Sezary syndrome ) 2 few . Closed accrual Cohort 2 Peripheral Tcell Lymphoma , unspecified , Anaplastic large cell lymphoma ( T null cell ) Primary Cutaneous Type 2 few . Open accrue Cohort 3 Cutaneous Tcell Lymphomas Peripheral Tcell LymphomaMore 2 . Closed accrual Cohort 4 Other Mature T cell LymphomasAny number . Open accrue Cohort 5 Cutaneous Tcell Lymphoma ( mycosis fungoides Sezary syndrome ) 2 fewerCohort 5 replicate cohort , identical # 1 Cohort 6 Peripheral Tcell Lymphoma ( PTCL ) , unspecified , Anaplastic large cell lymphoma ( T null cell ) Primary Cutaneous TypeMore 2 . Patients PTCL cohort 3 migrate cohort Cohort 7 Cutaneous Tcell Lymphoma ( mycosis fungoides Sezary syndrome ) Prior vorinostat requiredAny number Patients cutaneous Tcell lymphoma [ CTCL ( mycosis fungoides Sezary syndrome ) stage IB IVB eligible . Patients stage IB IIA refractory , intolerant , reach sixmonth longer response plateau least two prior therapy follow list : psoralen plus ultraviolet A irradiation ( PUVA ) , ultraviolet B ( UVB ) , electron beam therapy ( EBT ) , photophoresis , interferon , systemic cytotoxic chemotherapy , topical nitrogen mustard , topical carmustine ( BCNU ) . One qualify prior treatment must topical nitrogen mustard , topical carmustine phototherapy ( UVB , PUVA EBT ) . Topical steroid , systemic retinoids biologicals qualify . Patients stage IB IIA candidate topical nitrogen mustard , topical carmustine phototherapy ( UVB , PUVA EBT ) eligible enrollment . Patients may receive two systemic cytotoxic chemotherapy regimen . Steroids , retinoids , biologic agent , consider systemic cytotoxic chemotherapy . Radiolabeled monoclonal antibody therapy consider equivalent systemic cytotoxic chemotherapy regimen must count toward two prior systemic cytotoxic regimen . Patients stage IIBIVB 2 prior systemic cytotoxic chemotherapeutic regimen eligible . There restriction regard number prior topical therapy , skin irradiation , noncytotoxic systemic therapy ( i.e . PUVA , retinoids biologic , exception radiolabeled monoclonal antibody therapy ) patient group . After 24 patient enrolled arm , arm close , replicate arm constitute patient population open ( Cohort 5 ) . Patients peripheral Tcell lymphoma ( PTCL ) , unspecified , anaplastic large cell lymphoma , T null cell , primary cutaneous type , define Revised European American Lymphoma ( REAL ) /World Health Organization ( WHO ) classification ( 1618 ) , experienced disease progression receive prior standard treatment 2 prior systemic cytotoxic chemotherapeutic regimen eligible . Patients cutaneous T cell lymphoma ( Mycosis fungoides Sezary Syndrome ) peripheral T cell lymphoma define receive 2 prior systemic therapy experience disease progression include third independent arm . This arm protocol close accrual CTCL Amendment H. Patients mature T cell lymphoma include enrolled fourth arm . These include exclusively limited : Enteropathytype T cell lymphoma ; Hepatosplenic Tcell lymphoma ; Subcutaneous panniculitislike T cell lymphoma ; Angioimmunoblastic Tcell lymphoma ; Anaplastic large cell lymphoma . Patients must experience disease progression receive prior standard treatment . There limit number prior regimen . Primitive T cell neoplasms T cell leukemia enrol . Patients peripheral Tcell lymphoma , unspecified , anaplastic large cell lymphoma , T null cell , primary cutaneous type , define REAL/WHO classification ( 1618 ) , experienced disease progression receive prior standard treatment 2 prior systemic cytotoxic chemotherapeutic regimen eligible enrollment sixth arm trial . Patients cutaneous T cell lymphoma ( Mycosis fungoides Sezary Syndrome ) peripheral T cell lymphoma define # 1 receive number prior systemic therapy previously treat vorinostat include third independent arm . Patients enrol arm receive prior vorinostat experience disease progression , subsequent relapse , discontinue agent due toxicity . Disease measurable radiographic imaging , assess skin lesion , quantitating Sezary cell count . Patients must : age great equal 18 year performance status Eastern Cooperative Oncology Group ( ECOG ) 02 serious intercurrent illness life expectancy great 12 week give write informed consent female patient childbearing potential must negative pregnancy test within 4 week must use effective contraception sexually active male must use effective contraception Laboratory value ( perform less equal 14 day prior registration ) : absolute neutrophil count great equal 1000/microliter , platelet great equal l00,000/microliter , bilirubin ( total direct ) less equal 1.5x upper limit normal , aspartate aminotransferase ( AST ) less equal 3x upper limit normal , unless impairment due organ involvement lymphoma , creatinine le equal 1.5x upper limit normal , documented creatinine clearance great equal 60mL/min Cardiac study ( perform within 4 week registration ) : Ejection fraction great 50 % Echocardiogram Cardiac magnetic resonance imaging ( MRI ) , great equal 45 % multigated acquisition scan ( MUGA ) Scan . A stable dose ( great 1 month ) corticosteroid administer symptom management preclude enrollment . Tapering initiate follow administration depsipeptide . EXCLUSION CRITERIA : Patients unconfirmed diagnosis , Bcell lymphomas exclude . Prior concurrent malignancy curatively treat . Known central nervous system ( CNS ) lymphoma . Chemotherapy within 4 week , 6 week nitrosoureas mitomycin C. Biologics , Immunotherapy within 2 week . Human Immunodeficiency virus ( HIV ) seropositivity . Pregnant breastfeeding patient . Major surgery within 21 day . Uncontrolled infection uncontrolled medical illness . Patients receive prior histone deacetylase ( HDAC ) inhibitor therapy T cell lymphoma exclude except patient eligible enroll cohort 7 . Patients follow cardiac risk factor exclude study : Patients know cardiac abnormality : Congenital long QT syndrome Corrected QT interval ( QTc ) interval great 480 millisecond Patients myocardial infarction within 12 month study entry . Patients active coronary artery disease , e.g . angina define Canadian Class IIIV Patients electrocardiography ( ECG ) record screen show evidence cardiac ischemia ( ST depression great equal 2 mm ) . Any patient coronary artery disease suspect referred cardiology consultation active myocardial ischemia demonstrate patient exclude . If noninvasive imaging study equivocal , may necessary proceed coronary angiography . Patients congestive heart failure meet New York Heart Association ( NYHA ) Class II IV definition and/or ejection fraction le 45 % MUGA scan less 50 % echocardiogram and/or MRI . Patients history sustain ventricular tachycardia ( VT ) , ventricular fibrillation ( VF ) , Torsade de Pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) . Patients history arrhythmia Holter monitoring evaluation cardiology . Patients dilate , hypertrophic , restrictive cardiomyopathy prior treatment cause ( doubt , see ejection fraction criterion ) . Patients leave ventricular hypertrophy discuss Principal Investigator Study Chairman . Patients uncontrolled hypertension , i.e. , systolic blood pressure ( SBP ) great equal 160 mm Hg diastolic blood pressure ( DBP ) great equal 95 mm Hg . Patients cardiac arrhythmia require antiarrhythmic medication beta blocker calcium channel blocker . Patients digitalis discontinue exclude study . Patients Mobitz II second degree heart block pacemaker . Patients first degree Mobitz I second degree heart block , bradyarrhythmias sick sinus syndrome require Holter monitoring evaluation cardiology . Patients cardiac disease may exclude discretion principal investigator ( PI ) follow consultation cardiology .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Histone Acetylase</keyword>
	<keyword>Differentiation</keyword>
	<keyword>Sezary Syndrome</keyword>
	<keyword>Mycosis Fungoides</keyword>
	<keyword>CD 30 Lymphoma</keyword>
</DOC>